Early Diagnosis and Treatment of Parkinson's Disease
Wednesday, December 2, 2009 7:00 PM - 8:00 PM ET)

Description and Intended Audience:

This segment features Robert Hauser focusing on Early Diagnosis and Treatment of Parkinson's Disease. This activity is intended for neurologists, pharmacists, and other medical professionals with a specific interest in the management of Parkinson's disease.

Learning Objectives:

Upon completion of this Teleconference, participants should be able to:

Discuss the importance of early- versus delayed-start Parkinson's disease trials
Review the data from three recent studies of treatment of the early Parkinson's disease patient
Describe the potential disease-modifying effects of medications used to treat Parkinson's disease

Speaker Information and Disclosures:

Robert Hauser, MD
The University of South Florida, Professor
Director, Parkinson's Disease and Movement Disorders Center
Clinical Chair, Signature Interdisciplinary Program in Neuroscience
Tampa, FL

Robert Hauser, MD, MBA, is Professor of Neurology, Molecular Pharmacology and Physiology at the University of South Florida. He is Director of the Parkinson’s Disease and Movement Disorders Center, and Director of the Clinical Signature Interdisciplinary Program in Neuroscience. Dr. Hauser’s research focuses on the development of new treatments for Parkinson’s disease and other movement disorders. His expertise includes clinical trial design and execution. Dr. Hauser has authored or co-authored more than 150 peer-reviewed publications and has lectured frequently at scientific meetings around the world. He is a Past Chairman of the Interventional Neurology Section of the American Academy of Neurology, has served on the executive committee of the Parkinson Study Group and is currently a steering committee member for the NIH Neuroprotective Exploratory Trials (NET-PD) program.

Disclosure: Consultant Advisory / Speakers Bureau – Allergan Neuroscience, AlphMedica, ApotheCom, Axis Health Care, Bayer-Shering, Boehringer-Ingelheim, CNS Schering Plough, Centopharm, Embryon, Eisai, Genzyme, GlaxoSmithKline, Impax, Ipsen, Kyowa, Merck, Novartis, Ortho McNeil, Pfizer, Prestwick, Quintiles, Santhera, Schwarz Pharma, Schering Plough, Solvay, Teva, Valeant, Vernalis.

CE Information:

Physicians:

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Cine-Med and Astute Technology. Cine-Med is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Cine-Med, Inc. designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists:

Cine-Med is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is accredited for 0.1 CEU (1.0 contact hour) of continuing education credit. ACPE Universal Number 399-9999-09-025-H01-P. Activity type: knowledge-based.

How to get CE credit:

To receive credit, participants must view the webcast, register on this site, and successfully complete the post-test and evaluation (successful passing grade >=70%). Certificates can be printed on line.